Madrigal Pharmaceuticals Q3 EPS $(5.34) Misses $(4.92) Estimate
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals reported Q3 losses of $5.34 per share, missing the analyst consensus estimate of $4.92 by 8.54%. This represents a 12.42% increase in losses compared to the same period last year.
November 06, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Madrigal Pharmaceuticals reported higher than expected losses for Q3, which could negatively impact investor sentiment.
Madrigal Pharmaceuticals reported a larger than expected loss for Q3, missing analyst estimates by 8.54%. This could lead to a negative reaction from investors, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100